Review



loperamide induced functional constipation mouse model  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress loperamide induced functional constipation mouse model
    Acacetin improves gastrointestinal motility <t>in</t> <t>loperamide‐induced</t> <t>constipation</t> model. A loperamide‐induced constipation model was established in mice, different doses of acacetin were administered to the mice by oral gavaging (YWL‐high: 50 mg/kg/day; YWL‐medium: 25 mg/kg/day; YWL‐low: 10 mg/kg/day). The following parameters were monitored in an activated charcoal test after fasting treatment. (A‐D) Defecation initiation time; Fecal pellet counts at 8 h; Fecal water content; and intestinal propulsion rates. (E) Small intestine length measurements. (F) Gastrointestinal transit rates determined by activated charcoal propulsion. N = 6 animals in each group. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
    Loperamide Induced Functional Constipation Mouse Model, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 17 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/loperamide+induced+functional+constipation+mouse+model/pmc13035931-50-1-15?v=MedChemExpress
    Average 93 stars, based on 17 article reviews
    loperamide induced functional constipation mouse model - by Bioz Stars, 2026-07
    93/100 stars

    Images

    1) Product Images from "Acacetin Alleviates Loperamide‐Induced Functional Constipation by Inhibiting P53 ‐Mediated Apoptosis in Colonic Epithelial Cells"

    Article Title: Acacetin Alleviates Loperamide‐Induced Functional Constipation by Inhibiting P53 ‐Mediated Apoptosis in Colonic Epithelial Cells

    Journal: Neurogastroenterology and Motility

    doi: 10.1111/nmo.70298

    Acacetin improves gastrointestinal motility in loperamide‐induced constipation model. A loperamide‐induced constipation model was established in mice, different doses of acacetin were administered to the mice by oral gavaging (YWL‐high: 50 mg/kg/day; YWL‐medium: 25 mg/kg/day; YWL‐low: 10 mg/kg/day). The following parameters were monitored in an activated charcoal test after fasting treatment. (A‐D) Defecation initiation time; Fecal pellet counts at 8 h; Fecal water content; and intestinal propulsion rates. (E) Small intestine length measurements. (F) Gastrointestinal transit rates determined by activated charcoal propulsion. N = 6 animals in each group. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
    Figure Legend Snippet: Acacetin improves gastrointestinal motility in loperamide‐induced constipation model. A loperamide‐induced constipation model was established in mice, different doses of acacetin were administered to the mice by oral gavaging (YWL‐high: 50 mg/kg/day; YWL‐medium: 25 mg/kg/day; YWL‐low: 10 mg/kg/day). The following parameters were monitored in an activated charcoal test after fasting treatment. (A‐D) Defecation initiation time; Fecal pellet counts at 8 h; Fecal water content; and intestinal propulsion rates. (E) Small intestine length measurements. (F) Gastrointestinal transit rates determined by activated charcoal propulsion. N = 6 animals in each group. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Techniques Used:

    YWL extract and acacetin protect against loperamide‐induced apoptosis in colonic mucosal epithelial cells. (A) Cell viability after treatment with increasing doses of YWL extract. (B) Cell viability after treatment with increasing doses of acacetin. (C) Cell viability rescue by YWL extract and acacetin against loperamide‐induced toxicity. (D) TUNEL staining showing suppression of loperamide‐induced apoptosis by YWL and acacetin. (E) Immunoblots of cleaved caspase‐3 and Bax levels. (F) Immunoblots of phospho‐ and total P53 and AKT1 levels. (G) P53 transcriptional activity analysis. N = 3 independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
    Figure Legend Snippet: YWL extract and acacetin protect against loperamide‐induced apoptosis in colonic mucosal epithelial cells. (A) Cell viability after treatment with increasing doses of YWL extract. (B) Cell viability after treatment with increasing doses of acacetin. (C) Cell viability rescue by YWL extract and acacetin against loperamide‐induced toxicity. (D) TUNEL staining showing suppression of loperamide‐induced apoptosis by YWL and acacetin. (E) Immunoblots of cleaved caspase‐3 and Bax levels. (F) Immunoblots of phospho‐ and total P53 and AKT1 levels. (G) P53 transcriptional activity analysis. N = 3 independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Techniques Used: TUNEL Assay, Staining, Western Blot, Activity Assay

    Activating P53 signaling abrogates the protection of acacetin against loperamide‐induced apoptosis. (A) P53 transcriptional activity analysis after Nutlin‐3a treatment. (B) Immunoblotting of phospho‐P53 and phospho‐AKT1 levels. (C) Cell viability analysis by CCK‐8 assay showing abrogation of the protective effect of acacetin by Nutlin‐3a. (D) TUNEL staining demonstrating Nutlin‐3a abolishes the suppression of acacetin on loperamide‐induced apoptosis. N = 3 independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
    Figure Legend Snippet: Activating P53 signaling abrogates the protection of acacetin against loperamide‐induced apoptosis. (A) P53 transcriptional activity analysis after Nutlin‐3a treatment. (B) Immunoblotting of phospho‐P53 and phospho‐AKT1 levels. (C) Cell viability analysis by CCK‐8 assay showing abrogation of the protective effect of acacetin by Nutlin‐3a. (D) TUNEL staining demonstrating Nutlin‐3a abolishes the suppression of acacetin on loperamide‐induced apoptosis. N = 3 independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Techniques Used: Activity Assay, Western Blot, CCK-8 Assay, TUNEL Assay, Staining



    Similar Products

    loperamide induced functional constipation mouse model  (MedChemExpress)
    93
    MedChemExpress loperamide induced functional constipation mouse model
    Acacetin improves gastrointestinal motility <t>in</t> <t>loperamide‐induced</t> <t>constipation</t> model. A loperamide‐induced constipation model was established in mice, different doses of acacetin were administered to the mice by oral gavaging (YWL‐high: 50 mg/kg/day; YWL‐medium: 25 mg/kg/day; YWL‐low: 10 mg/kg/day). The following parameters were monitored in an activated charcoal test after fasting treatment. (A‐D) Defecation initiation time; Fecal pellet counts at 8 h; Fecal water content; and intestinal propulsion rates. (E) Small intestine length measurements. (F) Gastrointestinal transit rates determined by activated charcoal propulsion. N = 6 animals in each group. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
    Loperamide Induced Functional Constipation Mouse Model, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/loperamide+induced+functional+constipation+mouse+model/pmc13035931-50-1-15?v=MedChemExpress
    Average 93 stars, based on 1 article reviews
    loperamide induced functional constipation mouse model - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Acacetin improves gastrointestinal motility in loperamide‐induced constipation model. A loperamide‐induced constipation model was established in mice, different doses of acacetin were administered to the mice by oral gavaging (YWL‐high: 50 mg/kg/day; YWL‐medium: 25 mg/kg/day; YWL‐low: 10 mg/kg/day). The following parameters were monitored in an activated charcoal test after fasting treatment. (A‐D) Defecation initiation time; Fecal pellet counts at 8 h; Fecal water content; and intestinal propulsion rates. (E) Small intestine length measurements. (F) Gastrointestinal transit rates determined by activated charcoal propulsion. N = 6 animals in each group. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Journal: Neurogastroenterology and Motility

    Article Title: Acacetin Alleviates Loperamide‐Induced Functional Constipation by Inhibiting P53 ‐Mediated Apoptosis in Colonic Epithelial Cells

    doi: 10.1111/nmo.70298

    Figure Lengend Snippet: Acacetin improves gastrointestinal motility in loperamide‐induced constipation model. A loperamide‐induced constipation model was established in mice, different doses of acacetin were administered to the mice by oral gavaging (YWL‐high: 50 mg/kg/day; YWL‐medium: 25 mg/kg/day; YWL‐low: 10 mg/kg/day). The following parameters were monitored in an activated charcoal test after fasting treatment. (A‐D) Defecation initiation time; Fecal pellet counts at 8 h; Fecal water content; and intestinal propulsion rates. (E) Small intestine length measurements. (F) Gastrointestinal transit rates determined by activated charcoal propulsion. N = 6 animals in each group. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Article Snippet: A loperamide‐induced functional constipation mouse model was established using oral gavaging of loperamide hydrochloride (HY‐B0418A, MedChemExpress, Shanghai, China) suspension [ , ].

    Techniques:

    YWL extract and acacetin protect against loperamide‐induced apoptosis in colonic mucosal epithelial cells. (A) Cell viability after treatment with increasing doses of YWL extract. (B) Cell viability after treatment with increasing doses of acacetin. (C) Cell viability rescue by YWL extract and acacetin against loperamide‐induced toxicity. (D) TUNEL staining showing suppression of loperamide‐induced apoptosis by YWL and acacetin. (E) Immunoblots of cleaved caspase‐3 and Bax levels. (F) Immunoblots of phospho‐ and total P53 and AKT1 levels. (G) P53 transcriptional activity analysis. N = 3 independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Journal: Neurogastroenterology and Motility

    Article Title: Acacetin Alleviates Loperamide‐Induced Functional Constipation by Inhibiting P53 ‐Mediated Apoptosis in Colonic Epithelial Cells

    doi: 10.1111/nmo.70298

    Figure Lengend Snippet: YWL extract and acacetin protect against loperamide‐induced apoptosis in colonic mucosal epithelial cells. (A) Cell viability after treatment with increasing doses of YWL extract. (B) Cell viability after treatment with increasing doses of acacetin. (C) Cell viability rescue by YWL extract and acacetin against loperamide‐induced toxicity. (D) TUNEL staining showing suppression of loperamide‐induced apoptosis by YWL and acacetin. (E) Immunoblots of cleaved caspase‐3 and Bax levels. (F) Immunoblots of phospho‐ and total P53 and AKT1 levels. (G) P53 transcriptional activity analysis. N = 3 independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Article Snippet: A loperamide‐induced functional constipation mouse model was established using oral gavaging of loperamide hydrochloride (HY‐B0418A, MedChemExpress, Shanghai, China) suspension [ , ].

    Techniques: TUNEL Assay, Staining, Western Blot, Activity Assay

    Activating P53 signaling abrogates the protection of acacetin against loperamide‐induced apoptosis. (A) P53 transcriptional activity analysis after Nutlin‐3a treatment. (B) Immunoblotting of phospho‐P53 and phospho‐AKT1 levels. (C) Cell viability analysis by CCK‐8 assay showing abrogation of the protective effect of acacetin by Nutlin‐3a. (D) TUNEL staining demonstrating Nutlin‐3a abolishes the suppression of acacetin on loperamide‐induced apoptosis. N = 3 independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Journal: Neurogastroenterology and Motility

    Article Title: Acacetin Alleviates Loperamide‐Induced Functional Constipation by Inhibiting P53 ‐Mediated Apoptosis in Colonic Epithelial Cells

    doi: 10.1111/nmo.70298

    Figure Lengend Snippet: Activating P53 signaling abrogates the protection of acacetin against loperamide‐induced apoptosis. (A) P53 transcriptional activity analysis after Nutlin‐3a treatment. (B) Immunoblotting of phospho‐P53 and phospho‐AKT1 levels. (C) Cell viability analysis by CCK‐8 assay showing abrogation of the protective effect of acacetin by Nutlin‐3a. (D) TUNEL staining demonstrating Nutlin‐3a abolishes the suppression of acacetin on loperamide‐induced apoptosis. N = 3 independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Article Snippet: A loperamide‐induced functional constipation mouse model was established using oral gavaging of loperamide hydrochloride (HY‐B0418A, MedChemExpress, Shanghai, China) suspension [ , ].

    Techniques: Activity Assay, Western Blot, CCK-8 Assay, TUNEL Assay, Staining